Baclas, Shennamae H.
HRN: 21-70-99 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/22/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
08/22/2022
08/23/2022
IVT
500mg
Q8Hx3 Doses
S/P Repeat LTCS, Thickly MSAF
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominalReproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes